Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization

Andy Chen, T. Bains, S. Murray, R. Knight, K. Shoop, Joseph Bubalo, C. Fowler, Susan Slater, Richard Maziarz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34+cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 106CD34+progenitors/kg, our institutional minimum necessary for a single autologous transplant. On the basis of this relationship, a clinical guideline was developed which recommended pre-emptive use of plerixafor if the day 4 peripheral blood CD34+cell count was between 0.005 and 0.015/ml. A total of 166 consecutive subjects with lymphoma or plasma cell dyscrasias underwent G-CSF mobilization after adoption of this care pathway, and the mobilization failure rate was only 7% in patients managed per guideline. The median PBSC yield was 6.3 × 106 CD34+progenitors/kg with G-CSF (day 4 peripheral blood CD34 +cell>0.015/ml) and 4.9 × 10 6 CD34+progenitors/ kg with G-CSF+plerixafor (day 4 peripheral blood CD34+cell 0.005-0.015/ml). The median number of days of apheresis was 2 in both groups. This clinical guideline is an effective mobilization algorithm that minimizes mobilization failures, reduces poor apheresis yields, does not require risk factor identification and is simple to implement.

Original languageEnglish (US)
Pages (from-to)1526-1529
Number of pages4
JournalBone Marrow Transplantation
Volume47
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Hematopoietic Stem Cell Mobilization
Granulocyte Colony-Stimulating Factor
Blood Component Removal
Blood Cell Count
Guidelines
Blood Cells
Paraproteinemias
Autografts
Lymphoma
JM 3100

Keywords

  • algorithm
  • mobilization
  • Plerixafor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. / Chen, Andy; Bains, T.; Murray, S.; Knight, R.; Shoop, K.; Bubalo, Joseph; Fowler, C.; Slater, Susan; Maziarz, Richard.

In: Bone Marrow Transplantation, Vol. 47, No. 12, 12.2012, p. 1526-1529.

Research output: Contribution to journalArticle

Chen, Andy ; Bains, T. ; Murray, S. ; Knight, R. ; Shoop, K. ; Bubalo, Joseph ; Fowler, C. ; Slater, Susan ; Maziarz, Richard. / Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 12. pp. 1526-1529.
@article{4330f356f0d9446ebe2ab6f106c014ac,
title = "Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization",
abstract = "Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34+cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 106CD34+progenitors/kg, our institutional minimum necessary for a single autologous transplant. On the basis of this relationship, a clinical guideline was developed which recommended pre-emptive use of plerixafor if the day 4 peripheral blood CD34+cell count was between 0.005 and 0.015/ml. A total of 166 consecutive subjects with lymphoma or plasma cell dyscrasias underwent G-CSF mobilization after adoption of this care pathway, and the mobilization failure rate was only 7{\%} in patients managed per guideline. The median PBSC yield was 6.3 × 106 CD34+progenitors/kg with G-CSF (day 4 peripheral blood CD34 +cell>0.015/ml) and 4.9 × 10 6 CD34+progenitors/ kg with G-CSF+plerixafor (day 4 peripheral blood CD34+cell 0.005-0.015/ml). The median number of days of apheresis was 2 in both groups. This clinical guideline is an effective mobilization algorithm that minimizes mobilization failures, reduces poor apheresis yields, does not require risk factor identification and is simple to implement.",
keywords = "algorithm, mobilization, Plerixafor",
author = "Andy Chen and T. Bains and S. Murray and R. Knight and K. Shoop and Joseph Bubalo and C. Fowler and Susan Slater and Richard Maziarz",
year = "2012",
month = "12",
doi = "10.1038/bmt.2012.74",
language = "English (US)",
volume = "47",
pages = "1526--1529",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization

AU - Chen, Andy

AU - Bains, T.

AU - Murray, S.

AU - Knight, R.

AU - Shoop, K.

AU - Bubalo, Joseph

AU - Fowler, C.

AU - Slater, Susan

AU - Maziarz, Richard

PY - 2012/12

Y1 - 2012/12

N2 - Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34+cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 106CD34+progenitors/kg, our institutional minimum necessary for a single autologous transplant. On the basis of this relationship, a clinical guideline was developed which recommended pre-emptive use of plerixafor if the day 4 peripheral blood CD34+cell count was between 0.005 and 0.015/ml. A total of 166 consecutive subjects with lymphoma or plasma cell dyscrasias underwent G-CSF mobilization after adoption of this care pathway, and the mobilization failure rate was only 7% in patients managed per guideline. The median PBSC yield was 6.3 × 106 CD34+progenitors/kg with G-CSF (day 4 peripheral blood CD34 +cell>0.015/ml) and 4.9 × 10 6 CD34+progenitors/ kg with G-CSF+plerixafor (day 4 peripheral blood CD34+cell 0.005-0.015/ml). The median number of days of apheresis was 2 in both groups. This clinical guideline is an effective mobilization algorithm that minimizes mobilization failures, reduces poor apheresis yields, does not require risk factor identification and is simple to implement.

AB - Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34+cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 106CD34+progenitors/kg, our institutional minimum necessary for a single autologous transplant. On the basis of this relationship, a clinical guideline was developed which recommended pre-emptive use of plerixafor if the day 4 peripheral blood CD34+cell count was between 0.005 and 0.015/ml. A total of 166 consecutive subjects with lymphoma or plasma cell dyscrasias underwent G-CSF mobilization after adoption of this care pathway, and the mobilization failure rate was only 7% in patients managed per guideline. The median PBSC yield was 6.3 × 106 CD34+progenitors/kg with G-CSF (day 4 peripheral blood CD34 +cell>0.015/ml) and 4.9 × 10 6 CD34+progenitors/ kg with G-CSF+plerixafor (day 4 peripheral blood CD34+cell 0.005-0.015/ml). The median number of days of apheresis was 2 in both groups. This clinical guideline is an effective mobilization algorithm that minimizes mobilization failures, reduces poor apheresis yields, does not require risk factor identification and is simple to implement.

KW - algorithm

KW - mobilization

KW - Plerixafor

UR - http://www.scopus.com/inward/record.url?scp=84870835135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870835135&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.74

DO - 10.1038/bmt.2012.74

M3 - Article

C2 - 22562080

AN - SCOPUS:84870835135

VL - 47

SP - 1526

EP - 1529

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -